Browse studies

Find your next paid study

600 recruiting studies matching your filters

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refract…

Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)

Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisf…

AmyloidosisBasal Cell CarcinomaBiliary Tract Carcinoma+26 more

Estimated

~$10 – $6,250

Phase 1

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for s…

Metastatic Castration-resistant Prostate Cancer

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT07609225

Phase 1

A Phase Ib/II Open-label, Multi-center Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With an Androgen Receptor Pathway Inhibitor (ARPI) in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)

The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination wi…

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07226986

Phase 2

A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer

This is a four-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). …

PSMA PET-Positive Castration-Resistant Prostate Cancer

Estimated

~$10 – $8,750

Convergent TherapeuticsNCT06549465

Phase 2

Phase II Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc

This is an open-label, multi-site study of AR Blockade with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy…

Castration-resistant Prostate Cancer

Estimated

~$10 – $7,500

Edwin Posadas, MDNCT05534646

Phase 2

Phase II Trial of a Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is …

AdenocarcinomaProstate CancerNeoplasms+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07574541

Phase 1

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid…

Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06465069

Observational

Distance-Based Exercise to Preserve Function and Prevent Disability

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and a…

Localized Malignant Solid NeoplasmAnal CancerBladder (Urothelial, Transitional Cell) Cancer+16 more

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07059884

Phase 3

Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC With Lutetium 177Lu PSMA RLT (RECIPROCAL)

This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT im…

Metastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07200830

Phase 3

Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating pati…

Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT06931340

Phase 3

Randomized Phase III Trial of Rapid-Plan Knowledge-Based Planning vs. Human-Driven Planning for Prostate Cancer Radiotherapy

This phase III trial compares the effects of radiation therapy using RapidPlan, trademark, knowledge-based planning to human-driven planning in treating patien…

Prostate Carcinoma

Estimated

~$10 – $6,250

Mayo ClinicNCT06625034